Hydration and Physical Activity
To determine whether ingestion of a highly concentrated sodium-citrate beverage would induce hypervolemia in trained individuals and enhance running capacity in the heat.
Healthy, nonsmoking, male, moderately trained runners
Not specified.
Recruitment: Not specified.
Design: Double blind, placebo controlled, crossover trial
Blinding used (if applicable):
- Beverage was blind to the researcher conducting the trials and to the participant.
- To avoid any perceptive taste variations in the beverages, the participants were told that the study was designed to investigate varying concentrations of sodium in a pre-exercise beverage.
Intervention (if applicable)
- Subjects heat acclimated
- Trials randomized, separated by 1 - 3 weeks
- Control beverage: Low Na+, 10 mmol Na+/L-1, 0.58g NaCl, 42 mOsm/kg-1
- Experimental beverage: High Na+, 164 mmol Na+/L-1, 7.72g sodium-citrate with 4.5g NaCl, 253 mOsm/kg-1
- Volume: 10 mL/kg body mass (approximately 757 mL)
- Protocol:
- Participants voided on arrival to lab,
- Nude body mass recorded (+ 10g), catheter placement in left arm,
- Participants stood for 20 min before baseline blood samples were taken to ensure steady-state plasma volume and constituents.
- Beverage ingested in seven equal portions, one every 10 min.; Participants were required to walk approximately 1 min every 20 min to limit venous pooling;
- Before blood sampling, they were required to stand in one place for 20 min.
- Standardization of training effects:
- Each participant maintained training diary of duration, mode and intensity of activity, replicated for consistency preceding each trial
- Each participant completed a 40 min treadmill run at 50% V02max 48 h before each testing day and refrained from training until the experimental trial
- Same meal of participant's choice consumed the evening before testing
- No smoking, alcohol caffeinated beverages on the day before and day of test
- Standardized breakfast on day of testing: 1680 kJ, 13 g pro, 10 g fat, 65 g CHO, 2654 mg Na+ consumed 2-2.5 hr before experimentation
- 500 mL water given between breakfast and start of testing
- Exercise commenced 45 min after consuming beverage in climatically controlled chamber (32oC, 50% relative humidity, wind speed 1.5 ms).
- Speed of treadmill set to elicit 70% of temperate environment VO2max
- Exercise stopped when participant could not maintain exercise at given intensity or when ethically constrained rectal temperature of 39.5oC was reached.
Statistical Analysis
- Significance of effects of beverage and time on plasma volume, plasma osmolality, respiratory exchange ratio (RER), plasma sodium concentration: two-way repeated measures ANOVA
- Differences between means: Bonferroni-corrected post hoc tests
- Differences in fluid loss, urinary loss, mass loss, rate of change in urine [Na+], and plasma osmolality, RER, time to exercise termination, and slope of heart rate and rectal temperature: paired t-tests
- Relationships between selected dependent measures: Pearson product correlations.
- Differences considered statistically significant when P<0.05.
Timing of Measurements: Trials were separated by 1-3 weeks.
Dependent Variables
- Time on treadmill with speed at 70% of temperate-environment VO2max
- Rectal temperature: Thermister 400, Mallinckrodt, St. Louis, MO
- Skin temperatures: insulated thermistors (Type EU, Grant Instruments Ltd, Cambridge, UK) at 4 sites - biceps, calf, chest and thigh; mean temperature calculated
- Carbon dioxide production, VO2, and ventilation: measured for 2-min periods at 5 min. intervals using a gas-analysis system (Cortex Metalyser 3B, Borsdorf/Leipzig Germany)
- Urine [Na+ ], urine specific gravity: urine collected at baseline (-105 min) and after drinking (-45 min), immediatly before exercise (0 min), and at exhaustion.
- Hematocrit (Hct), Hemoglobin (Hb), plasma sodium concentration (P[Na +] and osmolality: blood samples taken immediately before urine sampling
- Change in plasma volume (PV) from baseline (%change PV) =100[(Hb0/Hbt) ((1-Hctt)/(1-Hct0))]-100%; t=time; 0=at baseline(-105 min); Hb=gm/100mL; Hct multiplied by .96, the.91 to correct for trapped plasma and the menous to whole blood Hct excess.
- Sweat loss: estimated by change in body mass corrected for urinary and blood losses and fluid intakes.
- Rates of sweat loss: approximated by dividing by exercise time.
- Final temperatures - rectal temperature (Trec) and skin temperature (Tskin):
mean of five mesurements recorded during the 2.5 min before the end point of the shortest exercise trial;
Independent Variables: Low sodium (Low Na+) or High sodium (High Na+) beverage
- Control beverage: Low Na+, 10 mmol Na+/L-1, 0.58g NaCl, 42 mOsm/kg-1
- Experimental beverage: High Na+, 164 mmol Na+/L-1, 7.72g sodium-citrate with 4.5g NaCl, 253 mOsm/kg-1
- Volume: 10 mL/kg body mass (approximately 757 mL)
Control Variables: None specified
Initial N: 9 males
Attrition (final N): Final N=8
Age: Mean + s.d. = 36 + 11 yr
Ethnicity: Not specified
Other relevant demographics: VO2max: 58 mL/kg-1/min (SD 5)
Anthropometrics :
- Weight (mean + s.d.) = 75.2 + 6.7 kg
- Height (mean + s.d.) = 179.5 + 5.5 cm
Location: University of Otago, Dunedin, New Zealand
Cardiovascular and Thermal Responses
Outcome |
Low Na+ |
High Na+ |
Significance (P) |
Plasma volume after drinking, before exercise (% change) |
0.0 +0.5 |
4.5+3.7 |
.04 |
Plasma volume during exercise (% change) |
-3.1+3.4 |
-2.5 + 2.6 |
n.s. |
Heart rate during exercise (bpm) |
161+ 16 |
157 + 11 |
n.s. |
Cardiovascular drift * (min-2) |
0.44 |
0.22 |
n.s. |
* rate of rise after initial 5 min of exercise
- Plasma volume decreased immediately before exercise in both trials.
- Time matched final heart rate was higher in Low Na, but differences were n.s. between conditions
- Mean Trec and mean Tskin increased over time in both trials (P < .001); no treatment effect was observed.
- Time matched final Trec was lower in High Na+ than in Low Na+ (P=0.00)
- Repeated measures ANOVA indicated a significant beverage effect (P=0.038) of changes in plasma volume before exercising to exhaustion.
Plasma osmolality and [Na+]
- Overall increase in plasma osmolality during exercise between High Na+ and Low Na+ = n.s.
- Rate of change in osmolality with High Na was slower than that of low Na+ (P=0.00)
- Plasma [Na+] was stable at rest after drinking for both High Na+and Low Na+ (n.s.)
- Plasma [Na+] increase during exercise: High Na+ = 0.8 mmol Na+L-1; Low Na+= 2.8 mmol Na+L-1 ; P=0.06
Fluid balance
- After ingestion of 757 mL of fluid in each condition, sweat rates and volumes were equivalent.
- More urine(mL) was produced throughout the Low Na+ trial (mean +s.d. for 8 subjects: 658.5+168.0) than during the High Na+ trial (492.0+196.5); (P<0.05)
- Rate of urine production (mL per h-1) throughout the Low Na+ trial (mean+s.d. for 8 subjects: 182+260.1) was greater (P<.05) than the High Na+ trial (130.1+252.1)
- During exercise, total sweat loss, rate of sweat loss, and rate of change in body mass= n.s.
Exercise Tolerance:
Core temperature increased during exercise in both conditions, reaching the 39.5oC. limit in 6/8 in Low Na+ and in 5/8 in High Na+trial.
Time to exercise exertion (mean+s.d.)
Reason for ending trial | Low Na+ | High Na+ | Significance (P) | |
39.5oC. | 46.4 + 4 | 57.9 + 6 | .04 | |
exhaustion | 75.3 + 21 | 96.1 + 22 | .03 | |
- Time-matched final rating of perceived exertion (RPE) was higher in the Low Na+ than in High Na+ trial (P=.04).
- The respiratory exchange ratio remained equivalent between beverage conditions ( Analysis included only 7/8 subjects)
Preexercise ingestion of a high-sodium beverage increased plasma volume before exercise and involved less thermoregulatory and perceived strain during exercise and increased exercise capacity in warm conditions.
University/Hospital: | University of Otago, New Zealand |
Quality Criteria Checklist: Primary Research
|
|||
Relevance Questions | |||
1. | Would implementing the studied intervention or procedure (if found successful) result in improved outcomes for the patients/clients/population group? (Not Applicable for some epidemiological studies) | Yes | |
2. | Did the authors study an outcome (dependent variable) or topic that the patients/clients/population group would care about? | Yes | |
3. | Is the focus of the intervention or procedure (independent variable) or topic of study a common issue of concern to dieteticspractice? | Yes | |
4. | Is the intervention or procedure feasible? (NA for some epidemiological studies) | Yes | |
Validity Questions | |||
1. | Was the research question clearly stated? | Yes | |
1.1. | Was (were) the specific intervention(s) or procedure(s) [independent variable(s)] identified? | Yes | |
1.2. | Was (were) the outcome(s) [dependent variable(s)] clearly indicated? | Yes | |
1.3. | Were the target population and setting specified? | Yes | |
2. | Was the selection of study subjects/patients free from bias? | No | |
2.1. | Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and without omitting criteria critical to the study? | Yes | |
2.2. | Were criteria applied equally to all study groups? | Yes | |
2.3. | Were health, demographics, and other characteristics of subjects described? | Yes | |
2.4. | Were the subjects/patients a representative sample of the relevant population? | No | |
3. | Were study groups comparable? | Yes | |
3.1. | Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT) | Yes | |
3.2. | Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline? | Yes | |
3.3. | Were concurrent controls or comparisons used? (Concurrent preferred over historical control or comparison groups.) | Yes | |
3.4. | If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for by using appropriate adjustments in statistical analysis? | N/A | |
3.5. | If case control study, were potential confounding factors comparable for cases and controls? (If case series or trial with subjects serving as own control, this criterion is not applicable.) | N/A | |
3.6. | If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., "gold standard")? | Yes | |
4. | Was method of handling withdrawals described? | N/A | |
4.1. | Were follow-up methods described and the same for all groups? | N/A | |
4.2. | Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) | N/A | |
4.3. | Were all enrolled subjects/patients (in the original sample) accounted for? | N/A | |
4.4. | Were reasons for withdrawals similar across groups? | N/A | |
4.5. | If diagnostic test, was decision to perform reference test not dependent on results of test under study? | N/A | |
5. | Was blinding used to prevent introduction of bias? | Yes | |
5.1. | In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? | Yes | |
5.2. | Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) | Yes | |
5.3. | In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? | N/A | |
5.4. | In case control study, was case definition explicit and case ascertainment not influenced by exposure status? | N/A | |
5.5. | In diagnostic study, were test results blinded to patient history and other test results? | N/A | |
6. | Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described in detail? Were interveningfactors described? | Yes | |
6.1. | In RCT or other intervention trial, were protocols described for all regimens studied? | Yes | |
6.2. | In observational study, were interventions, study settings, and clinicians/provider described? | N/A | |
6.3. | Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect? | ??? | |
6.4. | Was the amount of exposure and, if relevant, subject/patient compliance measured? | Yes | |
6.5. | Were co-interventions (e.g., ancillary treatments, other therapies) described? | N/A | |
6.6. | Were extra or unplanned treatments described? | N/A | |
6.7. | Was the information for 6.4, 6.5, and 6.6 assessed the same way for all groups? | N/A | |
6.8. | In diagnostic study, were details of test administration and replication sufficient? | Yes | |
7. | Were outcomes clearly defined and the measurements valid and reliable? | Yes | |
7.1. | Were primary and secondary endpoints described and relevant to the question? | Yes | |
7.2. | Were nutrition measures appropriate to question and outcomes of concern? | Yes | |
7.3. | Was the period of follow-up long enough for important outcome(s) to occur? | N/A | |
7.4. | Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/procedures? | Yes | |
7.5. | Was the measurement of effect at an appropriate level of precision? | Yes | |
7.6. | Were other factors accounted for (measured) that could affect outcomes? | Yes | |
7.7. | Were the measurements conducted consistently across groups? | Yes | |
8. | Was the statistical analysis appropriate for the study design and type of outcome indicators? | Yes | |
8.1. | Were statistical analyses adequately described and the results reported appropriately? | Yes | |
8.2. | Were correct statistical tests used and assumptions of test not violated? | Yes | |
8.3. | Were statistics reported with levels of significance and/or confidence intervals? | Yes | |
8.4. | Was "intent to treat" analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-response analysis)? | N/A | |
8.5. | Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)? | Yes | |
8.6. | Was clinical significance as well as statistical significance reported? | Yes | |
8.7. | If negative findings, was a power calculation reported to address type 2 error? | N/A | |
9. | Are conclusions supported by results with biases and limitations taken into consideration? | Yes | |
9.1. | Is there a discussion of findings? | Yes | |
9.2. | Are biases and study limitations identified and discussed? | Yes | |
10. | Is bias due to study's funding or sponsorship unlikely? | Yes | |
10.1. | Were sources of funding and investigators' affiliations described? | Yes | |
10.2. | Was the study free from apparent conflict of interest? | Yes | |